8-K: LENSAR Reports Strong Q1 2025 Results Amidst Alcon Acquisition

LENSAR announces a 34% revenue increase and a 33% rise in worldwide procedure volumes for Q1 2025, alongside its pending acquisition by Alcon.

Summary

• LENSAR reported its financial results for the first quarter of 2025, showing significant growth in several key areas.
• Total revenue increased by 34% to $14.2 million, compared to $10.6 million in the same quarter of the previous year.
• The company placed 14 ALLY Robotic Laser Cataract Systems during the quarter, bringing the total installed base to approximately 395 systems.
• Worldwide procedure volumes increased by 33% compared to the first quarter of 2024.
• Recurring revenue, which includes procedure, lease, and service revenue, grew by 22% in the trailing twelve months.
• The company's net loss for the quarter was $27.3 million, or ($2.32) per common share, primarily due to a change in warrant liability associated with a significant appreciation in the company's stock price.
• Selling, general, and administrative expenses increased to $11.1 million, largely due to acquisition-related costs associated with the proposed merger with Alcon Research, LLC.
• As of March 31, 2025, LENSAR had $25.2 million in cash, cash equivalents, and investments, including a $10.0 million cash deposit related to the Alcon Transaction.
• Due to the pending acquisition by Alcon, LENSAR will not be hosting an earnings conference call.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong revenue growth and procedure volume increases, but tempered by a significant net loss and the uncertainties surrounding the pending acquisition.

Positives

• LENSAR experienced a significant increase in revenue, growing by 34% compared to the first quarter of 2024.
• Worldwide procedure volumes increased by 33% year-over-year, indicating strong demand for LENSAR's technology.
• The company successfully placed 14 ALLY Systems during the quarter, expanding its installed base.
• Recurring revenue streams remain strong, accounting for a substantial portion of total revenue.
• The company's cash position improved due to a $10.0 million deposit related to the Alcon acquisition.

Negatives

• The company reported a significant net loss of $27.3 million for the quarter, primarily driven by changes in warrant liability.
• Selling, general, and administrative expenses increased substantially due to acquisition-related costs.
• EBITDA for the quarter ended March 31, 2025 was ($26.4) million, compared with ($1.4) million for the quarter ended March 31, 2024.

Risks

• The proposed merger with Alcon may not be completed in a timely manner or at all.
• Required regulatory approvals for the merger may be delayed or subject to unanticipated conditions.
• The anticipated benefits of the proposed merger may not be realized.
• Competing offers or acquisition proposals for LENSAR may emerge.
• The milestone related to the contingent value rights may not be achieved.
• Legal proceedings may be instituted against the company following the announcement of the merger.
• The company's stock price may decline significantly if the merger is not consummated.

Future Outlook

The press release contains forward-looking statements regarding the proposed acquisition of LENSAR by Alcon, including the expected timing of the closing of the Alcon Transaction and the proposed payment to be made to the company's stockholders.

Management Comments

• We had a solid start to 2025, as we successfully placed 40% more ALLY Systems in the first quarter of 2025, compared to the first quarter of 2024.
• Similarly, we achieved a substantial 34% increase in revenue and our worldwide procedure volumes were 33% above first quarter 2024 levels.
• Over the quarter, we began to see the positive impact of the ALLY Systems placed in the latter half of 2024 as they contributed to significantly higher procedure volume and recurring revenue year over year, said Nick Curtis, President and CEO of LENSAR.

Industry Context

LENSAR's focus on advanced robotic laser solutions for cataract treatment positions it within a competitive medical technology market. The pending acquisition by Alcon, a major player in eye care, suggests a strategic move to strengthen Alcon's position in the cataract surgery segment.

Comparison to Industry Standards

• Comparing LENSAR's growth to companies like Johnson & Johnson Vision, which also operates in the cataract surgery market, provides context.
• While specific growth rates vary, the 34% revenue increase and 33% procedure volume increase indicate strong performance relative to industry averages.
• The ALLY system's focus on robotic precision and AI integration aligns with the industry's trend toward advanced technology solutions.
• The acquisition by Alcon is similar to other strategic acquisitions in the medical device space, such as Medtronic's acquisition of Mazor Robotics, which aimed to enhance their surgical robotics capabilities.

Stakeholder Impact

• Shareholders may be impacted by the proposed merger with Alcon, pending stockholder approval.
• Employees may experience changes related to the integration of LENSAR into Alcon.
• Customers (surgeons and patients) may benefit from the combined resources and technologies of LENSAR and Alcon.
• Suppliers and creditors may be affected by the change in ownership and operational structure.

Next Steps

• A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed merger.
• The Company expects to file with the SEC a proxy statement and other relevant documents in connection with the proposed merger.

Key Dates

Keywords

LENSAR, ALLY System, Cataract Surgery, Alcon, Merger, Financial Results, Revenue, Procedure Volume, Robotic Laser, EBITDA